Blood test tracks diabetes risk in cystic fibrosis patients
NCT ID NCT03713437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a blood test can measure beta cell death in people with cystic fibrosis, which may help predict diabetes. About 40 participants with cystic fibrosis and healthy controls gave blood samples to check for a specific DNA marker. The goal was to understand when beta cells die and how that relates to diabetes development, not to provide treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
40 people
The number who actually took part.
- Started
-
Apr 2019
- Finished
-
Jun 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects with CF between the age of 0 and 21 years who are at their baseline health and have not started CFTR modulator therapy within the past 6 months. Healthy, age-matched controls between 0 and 21 years of age who do not have pancreatic endocrine or exocrine dysfunction.
- Ages
-
Up to 21 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for Cystic Fibrosis Subjects: * Age 0 - 21 years * Diagnosis of CF by two CF-causing mutations or elevated sweat chloride test * Normal glucose tolerance, impaired glucose tolerance, indeterminate glucose tolerance or CFRD * Pancreatic insufficiency Exclusion Criteria for Cystic Fibrosis Subjects: * Age \> 21 years * Diagnosis of type 1 or type 2 diabetes * Pregnancy * Oral or IV steroid use in the past 2 weeks * Pulmonary exacerbation requiring hospital admission in the past 2 weeks. * Initiation of CFTR corrector or potentiator medication within 6 months Inclusion Criteria for healthy, age-matched controls: * Age 0 - 21 years Exclusion Criteria for healthy, age-matched controls: * Age \> 21 years * Diagnosis of type 1 or type 2 diabetes or pre-diabetes * Disorders impacting pancreatic exocrine function * Pregnancy * Oral or IV steroid use in the past 2 weeks
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital and Medical Center
Omaha, Nebraska, 68114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Glucose sensor may flag diabetes risk in cystic fibrosis
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug